Calithera Biosciences

Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Calithera Biosciences, Inc. is a clinical stage precision oncology biopharmaceutical company, which engages in developing targeted therapies to redefine treatment for biomarker-specific patient populations. It also focuses on researching small molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.

SOUTH SAN FRANCISCO, April  14, 2020  (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, shared an update on business operations, including clinical program adjustments related to COVID-19.

Calithera Biosciences Provides Update on Business Operations

Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q4 2019 Results - Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif., Jan.  13, 2020  (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, provided today an overview of select expected fourth quarter 2019 financial results, initial 2020 financial guidance and upcoming corporate milestones. 

Calithera Biosciences Provides Overview of 2020 Corporate Milestones and Financial Guidance

SOUTH SAN FRANCISCO, Calif., Jan.  03, 2020  (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the compensation committee of the company’s board of directors granted one new employee a non-qualified stock option to purchase an aggregate of 28,000 shares of Calithera’s common stock, at a per share exercise price of $5.71, the closing trading price on December 31, 2019. The stock option vests monthly over four years and was granted pursuant to the Calithera Biosciences, Inc. 2018 Inducement Plan, or Inducement Plan, which was approved by Calithera’s board of directors in January 2018 in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option also has a ten year term and is subject to the terms and conditions of the Inducement Plan and the stock option agreement pursuant to which the option was granted.

Calithera Biosciences Announces  New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Dec.  05, 2019  (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the compensation committee of the company’s board of directors granted four new employees non-qualified stock options to purchase an aggregate of 52,500 shares of Calithera’s common stock, at a per share exercise price of $4.92, the closing trading price on November 29, 2019.  The stock options vest monthly over four years and were granted pursuant to the Calithera Biosciences, Inc. 2018 Inducement Plan, or Inducement Plan, which was approved by Calithera’s board of directors in January 2018 in accordance with Nasdaq Listing Rule 5653(c)(4). Each stock option also has a ten year term and is subject to the terms and conditions of the Inducement Plan and the stock option agreement pursuant to which the option was granted.

Calithera Biosciences  Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q3 2019 Results - Earnings Call Transcript

- First presentation of preclinical data for newly-announced IL4I1 immuno-oncology program

Calithera to Present Preclinical Data from IL4I1 and CD73 Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Calithera (CALA) completes patient enrollment in a phase II study evaluating a combination regimen of its lead candidate, telaglenastat, in patients with advanced kidney cancer.

Calithera (CALA) Completes Enrollment in Mid-Stage RCC Study

SOUTH SAN FRANCISCO, Calif., Oct.  01, 2019  (GLOBE NEWSWIRE) --  Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that new data from its research and development portfolio will be featured in two poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting 2019 in National Harbor, Maryland, taking place November 6-10.

Calithera Announces Acceptance of Two Abstracts for Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Responses observed in patients with microsatellite stable (MSS) colorectal cancer, a disease not historically sensitive to checkpoint inhibition Responses observed in patients with microsatellite stable (MSS) colorectal cancer, a disease not historically sensitive to checkpoint inhibition

New Data Presented at ESMO Congress 2019 from the Arginase Inhibitor INCB001158 Alone and in Combination with Pembrolizumab

SOUTH SAN FRANCISCO, Calif., Sept.  28, 2019  (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, presented today supporting data for its previously reported positive results from its randomized placebo-controlled Phase 2 ENTRATA study of telaglenastat (CB-839) in combination with everolimus in patients with advanced renal cell carcinoma (RCC). The telaglenastat-everolimus combination doubled the median progression-free survival (PFS) in heavily pre-treated patients with advanced RCC and had a well-tolerated safety profile. Telaglenastat is the first glutaminase inhibitor to demonstrate clinical activity for the treatment of cancer.

Data From Randomized Phase 2 ENTRATA Study Demonstrate Telaglenastat with Everolimus Improves Progression-Free Survival in Renal Cell Carcinoma

Investors need to pay close attention to Calithera (CALA) stock based on the movements in the options market lately.

Implied Volatility Surging for Calithera (CALA) Stock Options

SOUTH SAN FRANCISCO, Calif., Sept.  25, 2019  (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that Susan M. Molineaux, Ph.D, the company’s founder, president and chief executive officer, will present at the 2019 Cantor Global Healthcare Conference at 1:45 p.m. ET on Friday, October 4, 2019 in New York. The presentation will be webcast live, and available for replay, for up to 30 days at  www.calithera.com  in the Investor Relations section.

Calithera to Present at the 2019 Cantor Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Aug.  28, 2019  (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced its participation at two upcoming healthcare investor conferences in September.

Calithera to Participate in Wells Fargo Healthcare Conference and Citi 14th Annual Biotech Conference

Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q2 2019 Results - Earnings Call Transcript

AbbVie

Carnival

Denbury Resources

GigaMedia

Macerich

TG Therapeutics

Insiders may sell their stock for many reasons but they only buy it if believe they will profit. Here are 7 stocks to buy along with insiders.

7 Stocks on Sale the Insiders Are Buying

PRESIDENT AND CEO of Calithera Biosciences Inc (NASDAQ:CALA) Susan Molineaux bought 51,600 shares of CALA on 06/25/2019 at an average price of $3.88 a share.

Calithera Biosciences Inc (CALA) PRESIDENT AND CEO Susan Molineaux Bought $200,208 of Shares

Biohaven Pharmaceutical Hld

Eiger BioPharmaceuticals

Rockwell Medical

Tuesday was a breakout day for a few biotech companies, and that was the case even before news broke that the U.S. and China would be meeting at the G20 meeting in Japan.

Tuesday’s Top BioPharma Movers Deviating from the Market

Calithera Biosciences Inc (NASDAQ: CALA) shares were making a strong upward move Monday  following a clinical trial readout from the company.

Calithera's Kidney Cancer Drug Doubles Progression-Free Survival Vs. Chemotherapy

Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q1 2019 Results - Earnings Call Transcript

Calithera (CALA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Calithera (CALA) to Report a Decline in Earnings: What to Look Out for

Calithera (CALA) initiates a phase I/II study of the glutaminase inhibitor, telaglenastat (CB-839) in combination with Pfizer's poly adenosine diphosphate ribose polymerase inhibitor, Talzenna.

News for Calithera Biosciences Stock (CALA)